"A PHASE 1/2, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND, AGE DE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF INVENTPRISE¿S 25-VALENT PCV IN HEALTHY YOUNG ADULTS, CHILDREN AND INFANTS
- Registry ID
- CVIA 096
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- INVENTPRISE INC.
- Last update
- 2022-09-15
Conditions
Related clinical trials
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF ADJUNCTIVE RECOMBINANT HUMAN PLASMA GELSOLIN WITH
STANDARD OF CARE FOR MODERATE-TO-SEVERE ARDS DUE TO PNEUMONIA OR OTHER INFECTIONS
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED, LOT-TO-LOT CONSISTENCY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V116 IN ADULTS 18 TO 49 YEARS OF AGE
- A PHASE IIIB, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF GSK¿S MENINGOCOCCAL ABCWY VACCINE WHEN ADMINISTERED IN HEALTHY ADOLESCENTS AND ADULTS, PREVIOUSLY PRIMED WITH MENINGOCOCCAL ACWY VACCINE
- A PHASE 2B, RANDOMIZED, CONTROLLED, OBSERVER-BLIND, MULTI-CENTER, NON-INFERIORITY IMMUNOGENICITY AND SAFETY STUDY OF TWO FORMULATIONS OF GSK BIOLOGICALS¿ MENINGOCOCCAL ACWY CONJUGATE VACCINE
- SHORT-COURSE ANTIMICROBIAL THERAPY FOR PAEDIATRIC RESPIRATORY INFECTION (SAFER): A MULTICENTRE, RANDOMIZED, CONTROLLED, NON-INFERIORITY TRIAL
View on source registry